Respiratory syncytial virus vaccine

Abstract

Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.

1 - 22 . (canceled) 
     
     
         23 . A method of evoking protective immunity in a subject against respiratory syncytial virus infection, the method comprising:
 administering to a subject in need thereof an immunogenic composition comprising an ectodomain of a small hydrophobic protein of a respiratory syncytial virus,   wherein the ectodomain comprises SEQ ID NO: 18, and   wherein the composition comprises a carrier heterologous to the ectodomain.   
     
     
         24 . The method of  claim 23 , wherein said ectodomain has at least 80% sequence identity to SEQ ID NO: 17. 
     
     
         25 . The method of  claim 23 , wherein said ectodomain has a length of 31, 36, or 40 amino acids. 
     
     
         26 . The method of  claim 23 , wherein said ectodomain is an oligomer. 
     
     
         27 . The method of  claim 23 , wherein said ectodomain is linked to the carrier as a fusion protein. 
     
     
         28 . The method of  claim 23 , wherein said ectodomain is chemically linked to the carrier. 
     
     
         29 . The method of  claim 23 , wherein said carrier is an oligomer. 
     
     
         30 . The method of  claim 29 , wherein said oligomer is a pentamer. 
     
     
         31 . The method of  claim 23 , wherein said carrier is selected from the group consisting of cartilage oligomeric matrix protein (COMP), Lpp-56, and a virus-like particle. 
     
     
         32 . The method of  claim 23 , comprising administering said immunogenic composition to the subject prior to exposure of the subject to respiratory syncytial virus. 
     
     
         33 . The method of  claim 23 , wherein said carrier is a non-proteinaceous carrier. 
     
     
         34 . The method of  claim 33 , wherein said non-proteinaceous carrier is a liposome. 
     
     
         35 . The method of  claim 23 , wherein said ectodomain has at least 85% sequence identity to SEQ ID NO: 17. 
     
     
         36 . The method of  claim 23 , wherein said ectodomain has at least 90% sequence identity to SEQ ID NO: 17. 
     
     
         37 . The method of  claim 23 , wherein said ectodomain has at least 95% sequence identity to SEQ ID NO: 17. 
     
     
         38 . The method of  claim 23 , wherein said ectodomain comprises a sequence selected from the group consisting of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, and SEQ ID NO: 30. 
     
     
         39 . The method of  claim 23 , wherein said ectodomain is linked to a hinge or spacer sequence.